Interferon beta-1a

Relapsing-Remitting Multiple Sclerosis (adult and pediatric use from 12 years of age) Recombinant Betainterferon 1a is indicated for the treatment of multiple sclerosis characterized by the presence of relapses, and has been shown to reduce the number and severity of such relapses, as well as to stabilize disease progression.

The indication for recombinant Betainterferon 1a and its respective dosage must be determined exclusively by the physician and should be preceded by an accurate diagnosis regarding the stage of the disease, laboratory tests, magnetic resonance imaging, and other diagnostic parameters known by the specialist treating the patient.

Single Clinical Event Suggestive of Multiple Sclerosis (adult use)
Recombinant betainterferon 1a 44 µg is also indicated for use in patients who have experienced a single clinical event that is likely to represent the first sign of multiple sclerosis.